<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title42.html">
                                    Title 42
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/42CFR410.html">Part 410
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 410.29  Limitations on drugs and biologicals.
                            </h3>
                            <p class="depth0">Medicare part B does not pay for the following:</p><p class="depth1"><em>(a)</em> for outpatient diagnostic  services and Sec. 410.63(b) for blood clotting factors, and except for  EPO, any drug or biological that can be self-administered.</p><p class="depth1"><em>(b)</em> Any drug product that meets all of the following conditions:</p><p class="depth2"><em>(1)</em> The drug product was approved by the Food and Drug  Administration (FDA) before October 10, 1962.</p><p class="depth2"><em>(2)</em> The drug product is available only through prescription.</p><p class="depth2"><em>(3)</em> The drug product is the subject of a notice of opportunity for  hearing issued under section 505(e) of the Federal Food, Drug, and  Cosmetic Act and published in the Federal Register on a proposed order  of FDA to withdraw its approval for the drug product because it has  determined that the product is less than effective for all its labeled  indications.</p><p class="depth2"><em>(4)</em> The drug product is presently not subject to a determination by  FDA, made under its efficacy review program, that there is a compelling  justification of the drug product's medical need. (21 CFR 310.6 contains  an explanation of the efficacy review program.)</p><p class="depth1"><em>(c)</em> Any drug product that is identical, related, or similar, as  defined in 21 CFR 310.6, to a drug product that meets the conditions of  paragraph (b) of this section.  [51 FR 41339, Nov. 14, 1986, as amended at 55 FR 22790, June 4, 1990; 56  FR 43709, Sept. 4, 1991]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
